At the University of Buffalo, researchers conducted the first investigation to research risk factors for the vascular condition - chronic cerebrospinal venous insufficiency (CCSVI). The team investigated risk factors for CCSVI in volunteers without neurological disease and found a remarkable similarity between CCSVI and possibility of verified risk factors for multiple sclerosis (MS)…
More: continued […]
Filed under: Multiple Sclerosis on December 4th, 2011 | No Comments »
The first study to investigate risk factors for the vascular condition called CCSVI (chronic cerebrospinal venous insufficiency) in volunteers without neurological disease has identified what the researchers call a remarkable similarity between this condition and possible or confirmed risk factors for multiple sclerosis (MS)…
More: continued here
Filed under: Multiple Sclerosis on December 2nd, 2011 | No Comments »
Avi Dor, Ph.D…
More: continued here
Filed under: Multiple Sclerosis on November 29th, 2011 | No Comments »
John DeLuca, PhD, Vice President for Research at Kessler Foundation presented findings on the use of a behavioral technique for cognitive rehabilitation in people with multiple sclerosis (MS). Lead investigator was Nancy Chiaravalloti, PhD, director of the Neuropsychology & Neuroscience Laboratory at Kessler Foundation…
More: continued here
Filed under: Multiple Sclerosis on November 19th, 2011 | No Comments »
Two proteins conspire to promote a lethal neurological disease, according to a study published online this week in the Journal of Experimental Medicine*. Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, is a devastating neurodegenerative disorder that results in progressive loss of motor function and ultimately death…
More: continued here
Filed under: Multiple Sclerosis on November 17th, 2011 | No Comments »
A presentation at the American Society of Nephrology 44th Annual Meeting, showed study results of H.P. ActharŽ Gel, a natural adrenocorticotropic hormone (ACTH) designed for treatment of acute exacerbations of multiple sclerosis in adults, and as mono-therapy for the treatment of IS in infants and children under 2 years of age…
More: continued here
Filed under: Multiple Sclerosis on November 13th, 2011 | No Comments »
Medical researchers at the University of Alberta have discovered that an active ingredient in the Persian spice saffron may be a potential treatment for diseases involving neuroinflammation, such as multiple sclerosis. Chris Power and a team of researchers in the Faculty of Medicine & Dentistry recently published their findings in the peer-reviewed publication, The Journal […]
Filed under: Multiple Sclerosis on November 7th, 2011 | No Comments »
Multiple sclerosis (MS) is a chronic and disabling disease, in which a person’s central nervous system (brain, spinal cord and optic nerves) is attacked by their immune system, causing inflammation and onsets of neurological dysfunction, and over time results in progressive disability…
More: continued here
Filed under: Multiple Sclerosis on November 6th, 2011 | No Comments »
Researchers from the Department of Neurology at NYU Langone Medical Center identified for the first time that changes in the tissue located at the junction between the outer and inner layers of the brain, called “blurring”, may be an important, non-invasive biomarker for earlier diagnosis and the development of new therapies for degenerative brain conditions, […]
Filed under: Multiple Sclerosis on November 6th, 2011 | No Comments »
An experimental drug called Ocrelizumab has shown promise in a Phase 2 clinical trial involving 220 people with multiple sclerosis (MS), an often debilitating, chronic autoimmune disease that affects an increasing number of people in North America. It usually strikes young adults and is more common in women than in men…
More: continued here
Filed under: Multiple Sclerosis on November 6th, 2011 | No Comments »